The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Abstract
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, uncontrolled clinical studies. Patients with treatment refractory CD4+ CTCL (mycosis fungoides [MF], n = 38; Sézary syndrome [SS], n = 9) received 17 weekly infusions of zanolimumab (early-stage patients, 280 and 560 mg; advanced-stage patients, 280 and 980 mg). The primary end point was objective response (OR) as assessed by composite assessment of index lesion disease activity score. Secondary end points included physician's global assessment (PGA), time to response, response duration, and time to progression. ORs were recorded for patients in both CTCL types (MF, 13 ORs; SS, 2 ORs). In the high-dose groups (560 and 980 mg dose groups), a response rate of 56% was obtained with a median response of 81 weeks. Adverse events reported most frequently included low-grade infections and eczematous dermatitis. Zanolimumab showed marked clinical efficacy in the treatment of patients with refractory MF, with early onset of response, high response rate, and durable responses. The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Self-citationIn vivo estimates of division and death rates of human T lymphocytes.
Mclean, A. R., & Michie, C. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3707 · Cited by 270
Cited by
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
Clark, R. A., Watanabe, R., Teague, J. E., Schlapbach, C., Tawa, M. C., Adams, N., Dorosario, A. A., Chaney, K. S., Cutler, C. S., LeBoeuf, N. R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003008 · Cited by 367
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood · doi:10.1182/blood-2013-09-525915 · Cited by 93
“Reported efficacious single-agent therapies, including denileukin diftitox, bexarotene, deacetylase inhibitors (vorinostat, romidepsin, and panobinostat), and monoclonal antibodies for relapsed/refractory CTCL patients, have produced overall response rates (ORRs) of 24% to 45% in pivotal clinical trials.(6-13) Decreas…”
BackgroundSelf-citation
Metadata
- Authors
- Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Österborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K. M., Lisby, S., Baadsgaard, O., & Knox, S. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-06-01
- Volume
- 109
- Issue
- 11
- Pages
- 4655-4662
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2063259521
- Cited by
- 204
- References
- 4
- FWCI
- 17.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2006-12-062877
- The paper
- Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Österborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K. M., Lisby, S., Baadsgaard, O., & Knox, S. J. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. https://doi.org/10.1182/blood-2006-12-062877
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.